The African Development Bank (AfDB) and the Bill & Melinda Gates Foundation have unveiled a proposed financing facility designed to fundamentally reshape how African governments procure medicines and medical equipment. The Africa Medicines and Equipment Facility (AMEF), previewed during the International Maternal and Newborn Health Conference (IMNHC 2026) in Nairobi, would use the AfDB's balance-sheet strength to provide affordable loans that help countries buy essential health commodities earlier, more predictably, and on better terms. If approved by the AfDB Board in June, the facility could begin operations in Gambia and Senegal this year before scaling to 14 countries by 2027 — a development with far-reaching implications for health procurement suppliers across the continent.
The Facility: How AMEF Works
AMEF is being developed as a liquidity and execution platform — not a traditional development grant, but a blended-finance mechanism that leverages the AfDB's AAA-rated balance sheet alongside catalytic donor support to unlock affordable lending for health commodity purchases.
The core innovation lies in its incentive structure. The facility is built around what its designers call "disciplined concessionality" — a framework where better-planned, better-executed procurement unlocks better financing terms. Countries that demonstrate stronger procurement performance, including transparent tendering, competitive bidding, and timely delivery verification, gain access to more favorable loan conditions.
The Gates Foundation and other donors are considering a $200 million earmark specifically set aside to incentivize the facility's effectiveness. This concessional layer would subsidize interest rates and provide performance-linked bonuses, creating a direct financial reward for procurement excellence.
Key features of the AMEF include:
- Upfront liquidity: Countries receive financing before procurement cycles begin, eliminating the chronic payment delays that deter suppliers from African markets
- Pooled demand signaling: Aggregating procurement plans across multiple countries to achieve volume-based pricing
- Performance-linked terms: Lower interest rates and longer repayment periods tied to procurement quality metrics
- Supply chain coordination: Alignment with regional pooled procurement mechanisms like those managed by the Africa CDC
Why This Matters: Africa's Health Procurement Crisis
The AMEF addresses one of the most persistent structural weaknesses in African health systems. The continent imports 70-90% of its medicines and produces only 3% of global pharmaceuticals. More critically, Africa imports over 95% of its active pharmaceutical ingredients (APIs) — primarily from India and China — leaving health systems acutely vulnerable to supply chain disruptions.
According to WHO data, only about 35% of essential medicines are consistently available in public health facilities across the region. This availability gap is not primarily a demand problem — it is a financing and procurement execution problem. Governments frequently lack the upfront capital to place timely orders, face fragmented procurement systems that prevent economies of scale, and struggle with payment cycles that can stretch 12-18 months after delivery.
The consequences are severe. An estimated US$11 billion would be needed by 2030 to fund the growth of Africa's local pharmaceutical industry, according to industry analyses. Meanwhile, the disruption of traditional donor channels — particularly the restructuring of PEPFAR and the closure of USAID — has created new urgency. Countries that previously relied on US-funded procurement pipelines for HIV/AIDS medicines, malaria treatments, and maternal health supplies now face critical gaps.
The IMNHC 2026 conference in Nairobi, which convened over 1,800 health experts from 87 countries including 40 government delegations, underscored this urgency. Dr. Jean Kaseya, Director General of the Africa CDC, framed the challenge as a sovereignty issue: "It's not just a health issue... For me, it's a justice issue, a development issue, a sovereignty issue." His call for a "New Deal" on maternal health explicitly prioritized domestic financing mobilization and local manufacturing of essential health commodities.
AMEF Rollout: Countries and Timeline
The facility will follow a phased rollout:
Phase 1 (2026): Pilot in Gambia and Senegal. These two West African nations were selected as initial testing grounds, likely due to their manageable market size and existing AfDB engagement. The pilot will test AMEF's operational mechanics — from loan disbursement to procurement verification to performance assessment.
Phase 2 (2027): Scale to 12 additional countries, bringing the total to 14. Confirmed expansion countries include:
- Kenya — East Africa's largest economy with a rapidly expanding Social Health Authority
- Ethiopia — Africa's second most populous country, currently building a $2.5B fertilizer and industrial base
- Nigeria — The continent's largest pharmaceutical market, importing over $1.5B in medicines annually
- Tanzania — A priority country for health system strengthening with growing domestic manufacturing ambitions
The AfDB Board is expected to consider the facility for approval at its June 2026 meeting. If greenlit, AMEF would represent one of the most significant health procurement financing innovations in African development finance.
Procurement Implications: What Contractors Need to Know
The AMEF creates procurement opportunities across multiple categories:
Pharmaceutical Supplies
The most direct impact will be on suppliers of essential medicines, vaccines, and medical consumables. By providing upfront liquidity to governments, AMEF removes the payment risk that currently deters many international pharmaceutical companies from competing for African tenders. Suppliers who can demonstrate competitive pricing, reliable delivery, and quality certifications will find a more predictable market.
Key product categories include:
- Maternal and newborn health commodities (oxytocin, magnesium sulfate, antibiotics)
- HIV/AIDS antiretrovirals and testing supplies
- Malaria diagnostics and treatments
- Vaccines and cold chain supplies
- Essential medicines on the WHO Model List
Medical Equipment and Devices
The AMEF complements the AfDB's broader $3 billion health infrastructure program, which is funding modern diagnostic centers across the continent. Equipment procurement opportunities include:
- Advanced imaging systems (CT and MRI scanners)
- Radiotherapy and linear accelerators for cancer care
- Cardiac catheterization laboratories
- Digital pathology systems
- Point-of-care diagnostic devices
Consulting and Technical Assistance
The performance-linked nature of AMEF creates significant demand for consulting services:
- Procurement reform advisors: Helping governments redesign tender processes to meet AMEF performance criteria
- Supply chain management consultants: Optimizing warehousing, distribution, and last-mile delivery
- Health systems strengthening: Capacity building for national medical stores and procurement agencies
- Monitoring and evaluation: Independent verification of procurement outcomes and performance metrics
IT and Digital Systems
Modern procurement requires digital infrastructure. Opportunities include:
- E-procurement platforms: Electronic tendering and contract management systems
- Inventory management systems: Real-time tracking of medicine stock levels across health facilities
- Data analytics: Demand forecasting and supply chain optimization tools
- Financial management: Systems for tracking AMEF loan utilization and repayment
The Bigger Picture: AfDB's $6 Billion Health Push
The AMEF sits within a much larger AfDB commitment to health sector transformation. At the 2025 Annual Meetings, AfDB President Akinwumi Adesina announced a $6 billion investment plan comprising:
- $3 billion for quality health infrastructure: Modern hospitals, diagnostic centers, and treatment facilities across the continent, projected to create approximately 800 direct jobs and train over 500 healthcare professionals in oncology and cardiology
- $3 billion for local pharmaceutical manufacturing: Building domestic capacity to reduce import dependence, supported by the newly established African Pharmaceutical Technology Foundation — an entity designed to help African countries access intellectual property rights and secure the technology needed for local vaccine and medicine production
Together with AMEF, these initiatives represent a comprehensive approach: build the factories to make medicines locally, build the hospitals to deliver care, and build the financing mechanisms to ensure governments can actually buy what their populations need.
For procurement professionals, this translates into a multi-year pipeline spanning works (hospital and factory construction), supplies (equipment, medicines, raw materials), consulting (technical assistance, capacity building), and services (IT systems, supply chain management).
Countries and Regions Affected
The AMEF's initial 16-country footprint spans three African sub-regions:
West Africa: Gambia, Senegal, and Nigeria represent diverse procurement markets — from small-scale pilot environments to the continent's largest economy. Nigeria alone spends over $1.5 billion annually on pharmaceutical imports.
East Africa: Kenya, Ethiopia, and Tanzania are all expanding domestic health budgets. Kenya's Social Health Authority is restructuring the country's entire health financing architecture, while Ethiopia's industrial ambitions include pharmaceutical manufacturing zones.
Additional Countries: The remaining expansion countries have not been publicly confirmed, but the AfDB's existing health portfolio suggests likely candidates include Rwanda, Uganda, Mozambique, Ghana, Cote d'Ivoire, and the Democratic Republic of Congo — all countries with significant AfDB health engagements and large unmet pharmaceutical needs.
Companies targeting these markets should monitor AfDB tenders closely, as procurement notices for the pilot phase could appear as early as Q3 2026.
What This Means for Contractors
The AMEF represents a structural shift in how African health procurement is financed — moving from donor-dependent, fragmented purchasing toward creditworthy, performance-driven procurement at scale.
For international suppliers and contractors, the practical implications are:
- Register with AfDB procurement systems: Companies should ensure they are registered on the AfDB's procurement portal and have the necessary certifications for health commodity supply
- Monitor pilot country tenders: Gambia and Senegal will be the first markets to issue AMEF-backed procurement — watch for notices in health and medical tenders
- Prepare for volume-based competition: AMEF's pooled demand approach means larger contract sizes but more competitive pricing expectations
- Invest in quality certifications: WHO prequalification, ISO 13485 (medical devices), and GMP compliance will be essential to compete
- Build local partnerships: The facility's emphasis on procurement performance creates opportunities for firms that can demonstrate reliable in-country delivery networks
Looking Ahead
The AfDB Board's June decision on AMEF will be a watershed moment for health procurement in Africa. If approved, the facility would be the first of its kind — a development bank using its balance sheet explicitly to solve the liquidity crisis that has long plagued health commodity procurement across the continent.
With $200 million in potential donor incentives, a 16-country rollout plan, and alignment with Africa's broader push for pharmaceutical sovereignty, AMEF could unlock a procurement pipeline worth hundreds of millions annually. Combined with the AfDB's $6 billion health infrastructure and manufacturing programs, the continent's health and medical sector is entering a period of unprecedented investment.
Contractors and suppliers looking to position themselves should begin monitoring opportunities on BidsFactory now. Browse AfDB tenders, explore health sector opportunities, and track procurement notices from the pilot countries to stay ahead of this emerging market.
